Fig. 1.

Identification of model systems that reflect patient’s LGG and secondary GBM glycolytic phenotype. (A) mRNA levels comparison between LGGs (circles, n = 369) and secondary GBM (triangles, n = 11) containing an IDH^mut. The y-axes are displayed as log² from the mRNA counts, including the mean and SD in red. FDR corrected P-values obtained from a t-test, *P < 0.05; **P < 0.005; ***P < 0.001. A detailed version of the fold change and p-values is located in the Supplementary Table. (B) Kaplan–Meier survival plot generated from TCGA data stratified according to the grade and IDH mutational status. Blue: IDH^mut LGG patients. Red: secondary IDH^mut GBM patients. Orange: IDH^wt LGG patients. Green: IDH^wt GBM. (C) Growth rate of TS603 ND BT142 over time. (D) Kaplan–Meier survival plot for mice inoculated with IDH1^mut cell lines. (E) 2HG levels in both the tumor and contralateral tissue obtained from mice inoculated with IDH1^mut cell lines. (F) Immunostaining of tissue collected from our IDH1^mut mouse models displaying both hematoxylin and eosin and Ki67 as a marker of proliferation. Scale bars and percentage of staining are provided within the images. Significance based on t-test for 2HG levels and growth rate. *P < 0.05; **P < 0.005; ***P < 0.001.